Pfizer-BioNTech’s COVID-19 vaccine to generate $30B in sales: forecast

However, there are several challenges

Pfizer-BioNTech’s COVID-19 vaccine

Pfizer-BioNTech’s COVID-19 vaccine to generate $30B in sales: forecast. Source: pexels.com

Pfizer-BioNTech’s COVID-19 vaccine, BNT-162b2, is expected to generate $30 billion in sales by 2026, with peak sales of $13.9 billion in 2021, says GlobalData.

According to data, BNT-162b2’s sales are anticipated to decline by a staggering 76% in 2022 to $3.4 billion due to competition expected from future COVID-19 vaccine approvals. Nonetheless, COVID-19 vaccines will continue to be in demand beyond 2022 if COVID-19 turns out to be a seasonal or long-term concern.

The main challenge for BNT-162b2 is the ultra-cold storage requirement of -80°C. The vaccine is likely to suffer poor uptake in countries that have limited cold-chain logistics, while Moderna’s vaccine candidate mRNA-1273, which can be stored and shipped at -20°C, could be a more attractive alternative.

Pfizer-BioNTech’s BNT-162b2 vaccine breakthrough marks a significant turning point in the global battle against COVID-19. It raises hopes that life could return to normal by next winter; however, post-marketing surveillance will be critical to detect any rare serious adverse events, as there has not yet been an mRNA vaccine that has gone through the full regulatory pathway for approval
Keshalini Sabaratnam, Pharma Analyst at GlobalData

We’ve reported that 70% of British small business owners feel more confident about 2021 now that the vaccine has been rolled out.

SEE ALSO: